SEC Form 4 · accession 0001221355-26-000002
Allogene Therapeutics, Inc. · ALLO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joshua A Kazam
Director
Period of report
Jun 18, 2026
Accepted (ET)
Jun 23, 2026 · 4:35 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001737287
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 18, 2026 | M | 47,700 | $0.00 | A | 398,463 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF1,F2 | — | Jun 18, 2026 | M | 47,700 | D | — | — | Common Stock | 47,700 | 0 | D |
| Restricted Stock UnitF2 | — | Jun 18, 2026 | A | 95,400 | A | — | — | Common Stock | 95,400 | 95,400 | D |
Explanation of responses
- F1Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2018 Plan.
- F2Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date.